Skip to content

Strados System at Center of Excellence

Clinical Utility of Strados System in Periodically Recording Auscultation to Provide Replay Capability and Telemedicine Monitoring of Inpatients After Initial Clinical Assessment.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04485741
Enrollment
30
Registered
2020-07-24
Start date
2020-09-23
Completion date
2021-12-31
Last updated
2023-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Copd, Covid19

Brief summary

Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge patients from hospital. Of these, only auscultation routinely ceases upon discharge from Hospital. Healthcare utilization statistics have shown that for more than a decade, readmission after discharge for an exacerbation of COPD or severe asthma (or chronic heart failure) remains a major problem. The Strados System has been designed to extend the range of lung sound recording both geographically and temporally to improve the standard of care when access to continuous monitoring has been replaced by periodic or no monitoring. The primary purpose of this study is to assess the clinical utility of the Strados System in enabling periodic recording and reviewing of breath sounds in patients with chronic respiratory diseases, either in the ICU, or in less continuously monitored settings, including after inpatient discharge.

Interventions

DEVICERESP

The RESP device will be placed on the patient for periodic recording of auscultory sound.

Sponsors

Strados Labs, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Potential study participants will be recruited from within the Einstein Center of Excellence. Individuals who meet all of the following criteria are eligible for enrollment as study participants: 1. Males and females between the ages of 18-80: With documented physician-diagnosed COPD (chronic bronchitis dominant) or severe asthma, as defined either by the American Thoracic Society or the World Health Organization who are admitted for exacerbation, including those with active or suspected SARS-COV-2 infection OR Who are admitted with respiratory distress symptoms associated with SARS-COV-2 infection 2. Able to provide informed consent 3. Able to follow study procedures 4. Clinician assessment of the patient's current SARS-COV-2 status: negative or unlikely to be infected, RTPCR positive, or untested by clinically suspected 5. Accessible by telephone upon discharge

Exclusion criteria

Subjects who meet ANY of the following criteria are not eligible for enrollment: 1. Inability or unwillingness of the participant to give written informed consent 2. History of adverse reaction or allergy to Tegaderm 3. Unwillingness or inability to comply with study procedures 4. Scheduled for thoracic procedure 5. Inaccessible by telephone post-discharge

Design outcomes

Primary

MeasureTime frameDescription
Clinical utility as assessed by the PIPeriodic recording over 12 to 24 hoursTo assess the clinical utility of Strados Systems in enabling periodic recording and reviewing of lung breath sounds of inpatients with chronic respiratory diseases in ICU , and less continuously monitored settings.

Secondary

MeasureTime frame
Clinical utility as assessed by other cliniciansPeriodic recording over 12 to 24 hours
Correlation of RESP data with other measures of patient status.Periodic recording over 12 to 24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026